AB169521

Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)]

RabMAb
Recombinant
각 태그의 뜻

Be the first to review this product! 리뷰 제출

(10 제품이 사용된 논문 )

Rabbit Recombinant Monoclonal LRRK2 phospho S955 antibody. Suitable for WB and reacts with Human samples. Cited in 10 publications.

대체 명칭 보기

PARK8, LRRK2, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

1 이미지

Collaborator

Western blot - Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (AB169521)

Lanes 1 - 2:

Anti-DDDDK tag antibody

Lanes 3 - 4:

Western blot - Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (ab169521) at 1/2000 dilution

Lanes 5 - 6:

Western blot - Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (ab169521) at 1/10000 dilution

Lanes 1, 3 and 5:

HEK293T cells stably expressed with wild-type DDDDK-LRRK2

Lanes 2, 4 and 6:

HEK293T cells stably expressed with mutant DDDDK-LRRK2

Predicted band size: 286 kDa

false

This image is courtesy of Drs. Dario Alessi and Paul Davies (The University of Dundee)

주요 정보

Host species

Rabbit

Clonality

Monoclonal

Clone number

MJF-R11 (75-1)

Isotype

IgG

Carrier free

Reacts with

Human

Applications

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

style

left-column

제품 세부 정보

This antibody was developed with support of The Michael J. Fox Foundation (MJFF) with the assistance of a consortium of investigators to help accelerate LRRK2 research.

LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domain among its many protein interaction domains. LRRK2 is mutated in a significant number of Parkinson's disease(PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. The most common mutation replaces glycine 2019 with a serine that results in increased LRRK2 kinase activity. This indicates that inhibitors of LRRK2 kinase activity might be of therapeutic benefit for the treatment of Parkinson's disease and has stimulated much activity in this field of research. Based upon mass spectrometry findings, a number of other residues within LRRK2 have also been found to be phosphorylated as well.

It is of note that phosphorylation of Serine 955 is not thought to be the result of autophosphorylation of the kinase though currently, the physiological relevance of these phospho-sites is not clear. Thus with the generation of this phospho-specific antibody, it is MJFF's hope that investigators may have at hand a critical tool to assist in their research endeavors that might thereby lend further clarity to the field of LRRK2 and its role in PD pathogenesis.

Acknowledgements: The Michael J. Fox Foundation would like to acknowledge the assistance of the following laboratories and individuals, whose input, guidance and assistance in testing all phospho specific LRRK2 antibodies was critical:

• The Laboratory of Dr. Dario Alessi (University of Dundee) - Paul Davies, PhD
• The Laboratory of Dr. Mark Cookson (National Institute on Aging) - Alexandra Beilina, PhD
• The Laboratory of Dr. Johannes Gloeckner (Helmholtz Zentrum Munchen)
• The Laboratory of Dr. Takeshi Iwatsubo (University of Tokyo) - Genta Ito, PhD
• The Laboratory of Dr. Jeremy Nichols (The Parkinson's Institute)
• The Laboratory of Dr. Andrew West (University of Alabama)

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.

style

left-column

특성 및 보관 정보

제형

Liquid

Purification 테크닉

Affinity purification Protein A

보관 버퍼

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

배송 시 보관 조건

Conditional Ambient

적절한 단기 보관 기간

1-2 weeks

적절한 단기 보관 조건

+4°C

적절한 장기 보관 조건

-20°C

분주 정보

Upon delivery aliquot

style

left-column

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

The protein LRRK2 also known as leucine-rich repeat kinase 2 or dardarin is an enzyme with a molecular weight of approximately 286 kDa. It functions as a kinase meaning it adds phosphate groups to other proteins which affects their activity. LRRK2 is expressed in various tissues but it is highly abundant in the brain especially in regions such as the striatum and cortex. It has a significant role in cellular signaling processes due to its phosphorylation activity.

Biological function summary

LRRK2 interacts with cellular mechanisms by regulating cytoskeletal dynamics autophagy and vesicle trafficking. It is a part of a larger complex that includes other proteins involved in these processes. The kinase activity of LRRK2 plays an essential part in maintaining neuronal health and function. It influences the process of autophagy which is a way cells clean themselves by removing damaged components and recycling them.

Pathways

The action of LRRK2 is central to the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. In these pathways LRRK2 interacts with other proteins such as mTOR and RPS6KB1. It modulates cellular processes like growth proliferation and response to stressors. Its kinase activity affects the phosphorylation state of targets within the pathways hence influencing biological outcomes like survival and apoptosis.

LRRK2 mutations have a significant connection to Parkinson's disease and Crohn's disease. In Parkinson's disease mutated LRRK2 leads to abnormal protein aggregation linking to proteins such as alpha-synuclein. For Crohn's disease LRRK2 influences the immune response and intestinal inflammation. These connections highlight LRRK2's role in the pathogenesis and contribute to understanding these complex disorders.

style

left-column

style

left-column

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

타겟 정보

Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed : 17114044, PubMed : 20949042, PubMed : 21850687, PubMed : 22012985, PubMed : 23395371, PubMed : 24687852, PubMed : 25201882, PubMed : 26014385, PubMed : 26824392, PubMed : 27830463, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB29, RAB35, and RAB43 (PubMed : 23395371, PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421, PubMed : 38127736). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed : 26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed : 26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed : 29125462, PubMed : 30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed : 23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed : 17114044). Plays a role in synaptic vesicle trafficking (PubMed : 24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed : 25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed : 22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed : 22012985). Phosphorylates PRDX3 (PubMed : 21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed : 28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed : 27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed : 26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed : 18230735, PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29212815). Recruited by RAB29/RAB7L1 to overloaded lysosomes where it phosphorylates and stabilizes RAB8A and RAB10 which promote lysosomal content release and suppress lysosomal enlargement through the EHBP1 and EHBP1L1 effector proteins (PubMed : 30209220, PubMed : 38227290).

See full target information LRRK2 pS955

style

left-column

제품이 사용된 논문 (10)

Recent publications for all applications. Explore the 전체 목록 and refine your search

NPJ Parkinson's disease 9:21 PubMed36750568

2023

Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson's disease and pharmacodynamic biomarkers.

Applications

Unspecified application

Species

Unspecified reactive species

Jean-Marc Taymans,Eugénie Mutez,William Sibran,Laurine Vandewynckel,Claire Deldycke,Séverine Bleuse,Antoine Marchand,Alessia Sarchione,Coline Leghay,Alexandre Kreisler,Clémence Simonin,James Koprich,Guillaume Baille,Luc Defebvre,Kathy Dujardin,Alain Destée,Marie-Christine Chartier-Harlin

The Biochemical journal 479:1759-1783 PubMed35950872

2022

Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.

Applications

Unspecified application

Species

Unspecified reactive species

Alexia F Kalogeropulou,Elena Purlyte,Francesca Tonelli,Sven M Lange,Melanie Wightman,Alan R Prescott,Shalini Padmanabhan,Esther Sammler,Dario R Alessi

The Biochemical journal 478:3555-3573 PubMed34515301

2021

Impact of Type II LRRK2 inhibitors on signaling and mitophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Anna Tasegian,Francois Singh,Ian G Ganley,Alastair D Reith,Dario R Alessi

Scientific reports 10:17293 PubMed33057100

2020

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.

Applications

Unspecified application

Species

Unspecified reactive species

C P Gonzalez-Hunt,E A Thacker,C M Toste,S Boularand,S Deprets,L Dubois,L H Sanders

Proceedings of the National Academy of Sciences of 116:14979-14988 PubMed31292254

2019

The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.

Applications

Unspecified application

Species

Unspecified reactive species

Sven H Schmidt,Matthias J Knape,Daniela Boassa,Natascha Mumdey,Alexandr P Kornev,Mark H Ellisman,Susan S Taylor,Friedrich W Herberg

Disease markers 2018:5068701 PubMed30305853

2018

The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Liang-Che Chang,Tzu-Ping Chen,Wei-Ke Kuo,Chung-Ching Hua

Nature communications 9:3465 PubMed30150626

2018

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.

Applications

Unspecified application

Species

Unspecified reactive species

Eun-Jin Bae,Dong-Kyu Kim,Changyoun Kim,Michael Mante,Anthony Adame,Edward Rockenstein,Ayse Ulusoy,Michael Klinkenberg,Ga Ram Jeong,Jae Ryul Bae,Cheolsoon Lee,He-Jin Lee,Byung-Dae Lee,Donato A Di Monte,Eliezer Masliah,Seung-Jae Lee

The EMBO journal 37:1-18 PubMed29212815

2017

Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Purlyte,Herschel S Dhekne,Adil R Sarhan,Rachel Gomez,Pawel Lis,Melanie Wightman,Terina N Martinez,Francesca Tonelli,Suzanne R Pfeffer,Dario R Alessi

Scientific reports 6:31391 PubMed27503089

2016

Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.

Applications

Species

Unspecified reactive species

G Perera,M Ranola,D B Rowe,G M Halliday,N Dzamko

PloS one 9:e97988 PubMed24836358

2014

Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.

Applications

Species

Unspecified reactive species

Genta Ito,Tetta Fujimoto,Shogo Kamikawaji,Tomoki Kuwahara,Takeshi Iwatsubo

제품이 사용된 논문 모두 보기

style

left-column

style

left-column

style

right-column

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.

자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)]

Western blot - Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (AB169521)

관련 conjugated 항체와 다양한 조성의 항체 (1)

주요 정보

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

대체품

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

보완 제품

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity 정보

제품 세부 정보

특성 및 보관 정보

제형

Purification 테크닉

보관 버퍼

배송 시 보관 조건

적절한 단기 보관 기간

적절한 단기 보관 조건

적절한 장기 보관 조건

분주 정보

추가 정보

Biological function summary

Pathways

제품 프로토콜

타겟 정보

제품이 사용된 논문 (10)

Product promise